Naloxone Recalled Nationwide by Manufacturer
June 05—The opioid overdose reversal drug Naloxone has been voluntarily recalled by its maker Hospira, Inc., according to an announcement issued by the US Food and Drug Administration on Monday.
Hospira, Inc. recalled the single-use cartridge syringe system because of loose particulate matter on the plunger that has the low potential to cause local irritation and internal allergic reactions, the release said.
A label on the product recommends "visual inspection of the product for particulate matter and discoloration prior to administration," which may reduce the risk of infection.
Elvis Rosado, education and community outreach coordinator of Prevention Point in Philadelphia, said that the recall would not negatively impact the needle exchange program because they do not use Naloxone. Instead, the program prefers the brand name nasal spray by Adapt Pharma, Inc., known as Narcan, which does not require the use of a syringe.
"[Naloxone] is the generic one. We don't use that one," Rosado said. "I'm glad. That would've been a nightmare."
Hospira, Inc., has contacted wholesalers, distributers and hospitals regarding the recall. There have not yet been reports of any adverse events as a result of using the Naloxone cartridge syringe, the release said.
Naloxone Hydrochloride is used for the complete or partial reversal of a confirmed or suspected opioid overdose. Although it is a prescription product, Pennsylvania is among the states that do not require an individual prescription to receive the life-saving drug.